Crossing The Valley Of Death: New Funding Options For Preclinical And Early-Stage Drug Development

A risk-averse investment climate has made it more difficult for startups to find the funding needed to bring novel treatments into the clinic. However, alternative funding sources, investment models, and nontraditional investors are stepping in to fill the void. Our panel of experts will identify and discuss new funding opportunities and strategies for companies at preclinical and the early stages of clinical development.